Antineoplastic Agents

All Drugs and Chemicals

Oblimersen

G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide

Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.

A Phase I Study of G3139 Subcutaneous in Solid Tumors

A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors

Genta Incorporated

Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Oculocerebral Syndrome With Hypopigmentation

Neuroendocrine Tumor

Neuroepithelioma

Dacarbazine

Antineoplastic Agents, Alkylating

Alkylating Agents

Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2

Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2

Genasense® (G3139, oblimersen sodium)

Genasense followed by DTIC; then DTIC alone

DTIC alone; then Genasense followed by DTIC

This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase I Study of G3139 Subcutaneous in Solid Tumors	NCT00543231	Tumors	G3139, Oblimers...	18 Years -	Genta Incorporated
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine	NCT00542893	Advanced Melano...	Genasense® (G31... Genasense follo... DTIC alone; the...	18 Years -	Genta Incorporated
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine	NCT00542893	Advanced Melano...	Genasense® (G31... Genasense follo... DTIC alone; the...	18 Years -	Genta Incorporated

Spots Global Cancer Trial Database for nci ctc

Every month we try and update this database with for nci ctc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nci ctc

Every month we try and update this database with for nci ctc cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nci ctc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.